NYSEAMERICAN:IBIO iBio (IBIO) Stock Forecast, Price & News $0.30 0.00 (0.00%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$0.30▼$0.3250-Day Range N/A52-Week Range$0.26▼$8.75Volume274,349 shsAverage Volume1.56 million shsMarket Capitalization$5.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media iBio MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.33% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.70Based on 3 Articles This WeekInsider TradingSelling Shares$31,598 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.38 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for iBio. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.33% of the float of iBio has been sold short.Short Interest Ratio / Days to CoveriBio has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iBio has recently increased by 6.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldiBio does not currently pay a dividend.Dividend GrowthiBio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IBIO. Previous Next 3.2 News and Social Media Coverage News SentimentiBio has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for iBio this week, compared to 1 article on an average week.Search Interest9 people have searched for IBIO on MarketBeat in the last 30 days. MarketBeat Follows5 people have added iBio to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, iBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,598.00 in company stock.Percentage Held by InsidersOnly 2.38% of the stock of iBio is held by insiders.Percentage Held by InstitutionsOnly 6.79% of the stock of iBio is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioiBio has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About iBio (NYSEAMERICAN:IBIO) StockiBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc, as well as a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Read More IBIO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IBIO Stock News HeadlinesSeptember 22, 2023 | finanznachrichten.deiBio, Inc.: iBio Announces Amendment to Credit Agreement with WoodforestSeptember 21, 2023 | finance.yahoo.comiBio Announces Amendment to Credit Agreement with WoodforestSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 15, 2023 | marketwatch.comiBio Inc. stock falls Tuesday, underperforms marketAugust 14, 2023 | marketwatch.comiBio Inc. stock rises Monday, outperforms marketAugust 14, 2023 | finance.yahoo.comiBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical DevelopmentAugust 1, 2023 | investing.comPharos IBio Co Ltd (388870)July 5, 2023 | marketwatch.comiBio Inc. stock rises Wednesday, outperforms marketSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsJune 27, 2023 | finance.yahoo.comPlant-based Expression Systems Market - Vaccines and Monoclonal Antibodies accounted for the Largest Market Share | Latest InsightAce StudyJune 27, 2023 | finance.yahoo.comiBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of GrowthJune 16, 2023 | marketwatch.comiBio Inc. stock rises Thursday, outperforms marketJune 13, 2023 | marketwatch.comiBio Shares Rise 14% After Research Deal With National Institute of Allergy and Infectious DiseasesJune 13, 2023 | investorplace.comWhy Is iBio (IBIO) Stock Up 16% Today?June 12, 2023 | finance.yahoo.comiBio Forges Research Collaboration with the National Institutes of HealthJune 6, 2023 | finance.yahoo.comiBio Expands Tech Stack with EngageTx™; Adds TROP-2 Bispecific to Development PipelineMay 26, 2023 | msn.comFrom Radiohead reimaginings to musical molluscs: Glasgow Jazz Festival broadens its horizonsMay 26, 2023 | msn.comFrom Radiohead reimaginings to musical moluscs: Glasgow Jazz Festival broadens its horizonsMay 18, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Ibio (IBIO), SeaStar Medical Holding (ICU) and Viking Therapeutics (VKTX)May 12, 2023 | msn.comiBio: Q3 Earnings InsightsMay 10, 2023 | marketwatch.comiBio Inc. stock falls Wednesday, underperforms marketMay 10, 2023 | marketwatch.comiBio Inc. stock falls Monday, underperforms marketMay 9, 2023 | finance.yahoo.comiBio to Participate in the JMP Securities Life Sciences ConferenceMay 4, 2023 | marketwatch.comiBio Inc. stock rises Tuesday, outperforms marketApril 23, 2023 | marketwatch.comiBio Inc. stock rises Friday, outperforms marketApril 17, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Kura Oncology (KURA) and Ibio (IBIO)April 13, 2023 | finance.yahoo.comPlasma Protease C1 Inhibitor Market size to grow by USD 1.7 billion from 2021 to 2026, Driven by the increasing R&D - TechnavioSee More Headlines Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Email Address IBIO Company Calendar Last Earnings11/15/2021Today9/26/2023Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:IBIO Previous SymbolNASDAQ:IBIO CUSIPN/A CIK1420720 Webwww.ibioinc.com Phone(979) 446-0027Fax302-356-1173Employees105Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,300,000.00 Net MarginsN/A Pretax Margin-11,133.67% Return on Equity-150.09% Return on Assets-79.33% Debt Debt-to-Equity Ratio0.04 Current Ratio1.22 Quick Ratio1.22 Sales & Book Value Annual Sales$2.38 million Price / Sales2.13 Cash FlowN/A Price / Cash FlowN/A Book Value$7.27 per share Price / Book0.04Miscellaneous Outstanding Shares16,800,000Free Float16,398,000Market Cap$5.06 million OptionableNot Optionable Beta-3.14 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Martin B. Brenner D.V.M. (Age 52)Ph.D., CEO & Chief Scientific Officer Comp: $578.3kMr. Robert B. Kay (Age 83)Interim Sec. & Interim Treasurer Comp: $92.69kMr. Felipe Duran (Age 43)Chief Financial Officer Stephen KilmerInvestor Relations OfficerMr. Marc Banjak J.D.Gen. CounselMs. Lisa MiddlebrookChief HR OfficerMore ExecutivesKey CompetitorsAddex TherapeuticsNASDAQ:ADXNULURUOTCMKTS:ULURDMK PharmaceuticalsNASDAQ:DMKJaguar HealthNASDAQ:JAGXHoth TherapeuticsNASDAQ:HOTHView All CompetitorsInsiders & InstitutionsMartin BrennerSold 5,011 sharesTotal: $1,553.41 ($0.31/share)Citadel Advisors LLCBought 200 shares on 8/15/2023Ownership: 0.000%Martin BrennerSold 4,515 sharesTotal: $2,302.65 ($0.51/share)Avantax Planning Partners Inc.Bought 155,000 shares on 7/18/2023Ownership: 0.923%Martin BrennerSold 47,020 sharesTotal: $27,741.80 ($0.59/share)View All Insider TransactionsView All Institutional Transactions IBIO Stock - Frequently Asked Questions Should I buy or sell iBio stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IBIO, but not buy additional shares or sell existing shares. View IBIO analyst ratings or view top-rated stocks. Are investors shorting iBio? iBio saw a increase in short interest in August. As of August 31st, there was short interest totaling 296,700 shares, an increase of 6.1% from the August 15th total of 279,600 shares. Based on an average daily volume of 727,900 shares, the short-interest ratio is presently 0.4 days. Approximately 1.3% of the company's shares are short sold. View iBio's Short Interest. How were iBio's earnings last quarter? iBio, Inc. (NYSEAMERICAN:IBIO) issued its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($1.00) EPS for the quarter, beating analysts' consensus estimates of ($1.25) by $0.25. The biotechnology company had revenue of $0.21 million for the quarter. When did iBio's stock split? iBio shares reverse split before market open on Tuesday, October 11th 2022. The 1-25 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of iBio own? Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA). What is iBio's stock symbol? iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO." Who are iBio's major shareholders? iBio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Avantax Planning Partners Inc. (0.92%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Martin Brenner and Robert Matthew Lutz. View institutional ownership trends. How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is iBio's stock price today? One share of IBIO stock can currently be purchased for approximately $0.30. How much money does iBio make? iBio (NYSEAMERICAN:IBIO) has a market capitalization of $5.06 million and generates $2.38 million in revenue each year. How many employees does iBio have? The company employs 105 workers across the globe. How can I contact iBio? iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (979) 446-0027, via email at ir@ibioinc.com, or via fax at 302-356-1173. This page (NYSEAMERICAN:IBIO) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.